The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Narjust Florez, MD
Associate director of the Cancer Care Equity Program, Thoracic medical oncologist, Dana-Farber Cancer Institute; Assistant professor of medicine, Harvard Medical School; Associate editor, JAMA Oncology
Lauren Keil
Senior research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Rebekah Kaufman, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Oyepeju Abioye-Akintola, MD, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial. 
Drugs & Targets

FDA approves Hyrnuo for HER2-mutated NSCLC

FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Byline
Narjust Florez, MD
Associate director of the Cancer Care Equity Program, Thoracic medical oncologist, Dana-Farber Cancer Institute; Assistant professor of medicine, Harvard Medical School; Associate editor, JAMA Oncology
Lauren Keil
Senior research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Rebekah Kaufman, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Oyepeju Abioye-Akintola, MD, MSc
Research assistant, Florez Laboratory, Dana-Farber Cancer Institute
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account